D017B8Z
Brachytherapy Peripheral Nerve to None with Iridium 192 (Ir-192), Low Dose Rate (LDR) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | D Radiation Therapy |
| Body System | 0 Central and Peripheral Nervous System |
| Operation | 1 Brachytherapy |
| Body Part | 7 Peripheral Nerve |
| Approach | B Low Dose Rate (LDR) |
| Device | 8 Iridium 192 (Ir-192) |
| Qualifier | Z None |
Procedure Overview
Brachytherapy of the central and peripheral nervous system is a radiation treatment in which a radioactive source is placed directly into or next to nervous system tissue, most often within the cavity left after a brain tumor is surgically removed. Rather than aiming beams through the skull from an external machine, this approach delivers radiation from a source positioned at very close range, allowing a concentrated dose to the tissue at highest risk of tumor recurrence while limiting exposure to the rest of the brain.
It is used selectively, often for certain malignant brain tumors where the surgical team places catheters or radioactive seeds at the time of tumor resection, or in a planned procedure shortly afterward. The therapy may involve a temporary source removed after the treatment period or, less commonly, permanently implanted material that decays over time.
Anatomy & Axis Detail
Peripheral Nerve
When brachytherapy targets a peripheral nerve, sources are typically placed intraoperatively into the tumor bed following resection of a nerve sheath tumor or a soft tissue sarcoma abutting a major nerve trunk, delivering dose to the tissue plane around the nerve to reduce local recurrence while limiting exposure to nearby skin, muscle, and vasculature. Because peripheral nerves run through soft tissue rather than a protective bony canal, source placement must account for the nerve's mobility and its relationship to adjacent structures that were disturbed during surgery. Functional nerve preservation is a central concern, so the specific nerve or plexus segment treated should be documented clearly, distinguishing this application from brachytherapy delivered to the brain, brain stem, or spinal cord.
Modality Qualifier: Low Dose Rate (LDR)
Low Dose Rate (LDR) denotes brachytherapy using a source of lower activity that remains implanted or applied over an extended period, from many hours to a few days, exploiting continuous low-level irradiation for tumor control. This differs from High Dose Rate (HDR), which compresses the same general goal into brief, higher-intensity sessions, and LDR is often chosen for permanent seed implants such as certain prostate treatments.
Isotope: Iridium 192 (Ir-192)
Iridium-192 is a gamma-emitting radioisotope used almost exclusively for high-dose-rate or pulsed-dose-rate brachytherapy, delivered via remote afterloader through catheters or applicators placed in or near the tumor. It allows a shaped, temporary dose to sites like the cervix, prostate, or breast cavity, then the source is withdrawn rather than left implanted, distinguishing it from permanent seed isotopes such as I-125 or Pd-103.
Coding & Documentation
Coding requires documentation that a radioactive source was physically placed within or adjacent to nervous system tissue, along with whether the source was intended as a temporary placement to be removed later or a permanent implant, since this determines the qualifier. The operative report should identify the specific nervous system structure treated and the isotope or device used to deliver the dose.
A frequent error is coding the catheter or applicator placement itself as the therapy code when the radioactive source has not yet been loaded, since some brachytherapy is delivered in a staged fashion with the source inserted afterward in a separate procedure. Coders should also make sure the resection of the tumor, if performed in the same session, is captured with a separate procedure code rather than folded into the radiation code.
Commonly Confused With
This family is commonly confused with Beam Radiation of the nervous system, since both treat the same body system with therapeutic radiation; the difference is that brachytherapy places the source directly at the treatment site rather than delivering radiation from an external machine. It is also sometimes confused with the surgical placement of a drug-delivery wafer or other implant during tumor resection, which is coded as a device implantation rather than radiation therapy unless the material itself is radioactive.